Venclax 100 mg (Venetoclax) Tablets

Venclax 100 mg (Venetoclax) is a targeted anticancer medicine used in the treatment of specific blood cancers. It works by selectively inhibiting the BCL-2 protein, which helps cancer cells survive longer than normal cells. By blocking this protein, Venetoclax promotes the natural death of abnormal cancer cells and helps reduce the progression of the disease.

This medicine is commonly prescribed for adults with Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), including patients with high-risk genetic abnormalities. It is also used in combination with other anticancer therapies for certain patients diagnosed with Acute Myeloid Leukemia (AML) who may not be suitable for intensive chemotherapy.

Therapeutic Benefits:

• Helps reduce the number of abnormal cancer cells.
• Supports long-term disease management in CLL and SLL.
• May improve treatment response in eligible AML patients.
• Targets cancer cells while minimizing effects on healthy cells.
• Used as part of modern precision oncology treatment strategies.
• Can be prescribed alone or in combination with other therapies depending on the treatment plan.

Each film-coated tablet contains:

Active Ingredient:

• Venetoclax USP – 100 mg

Pharmacological Class:

• BCL-2 (B-cell lymphoma-2) Inhibitor
• Targeted Antineoplastic Agent

Dosage Form:

• Film-Coated Tablet

Mechanism of Action:
Venetoclax selectively binds to the BCL-2 protein, a key survival factor found in many blood cancer cells. By inhibiting BCL-2 activity, the medicine restores the body's natural process of programmed cell death (apoptosis), helping eliminate malignant cells and control disease progression.

Excipients:
Contains pharmaceutical-grade inactive ingredients required for tablet formulation, stability, coating, and absorption.

Important: Always use this medicine exactly as prescribed by a qualified healthcare professional experienced in oncology treatment.

Standard Administration

• Take the tablet orally once daily.
• Swallow whole with water.
• Take with food at approximately the same time each day.
• Do not crush, chew, split, or break the tablet.

Dose Escalation

For many patients, treatment begins with a gradual dose increase over several weeks to reduce the risk of tumor lysis syndrome (TLS), a potentially serious treatment-related complication.

Missed Dose

• If a dose is missed and less than 8 hours have passed, take it as soon as possible.
• If more than 8 hours have passed, skip the missed dose and continue with the regular schedule.
• Do not take two doses at the same time to make up for a missed dose.

Hydration Guidance

Patients may be advised to drink adequate fluids before and during treatment, particularly when starting therapy, to help reduce the risk of treatment-related complications.

Monitoring Requirements

Regular blood tests and medical monitoring may be required to assess treatment response, kidney function, liver function, blood cell counts, and electrolyte levels throughout therapy.

Important Usage Instructions

• Follow the prescribed dose-escalation schedule carefully.
• Attend all scheduled medical appointments and laboratory assessments.
• Inform your healthcare provider about all medicines, supplements, and herbal products you are taking.
• Avoid grapefruit, Seville oranges, and star fruit unless specifically approved by your healthcare provider, as these may affect Venetoclax levels in the body.
• Do not discontinue treatment without consulting your physician.